NCT05660811 - Optimal Antiplatelet Therapy Following Left Atrial Appendage Closure in Dialyzed Patients | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 28, 2022

Primary Completion Date

June 30, 2026

Study Completion Date

June 30, 2026

Conditions

Atrial Fibrillation

Interventions

DRUG

short postimplantation dual antiplatelet therapy

continuing dual antiplatelet therapy up until 6 months after left atrial appendage occlusion with Amplatzer Amulet

DRUG

extended postimplantation dual antiplatelet therapy

stopping dual antiplatelet therapy after 30 days after left atrial appendage occlusion with Amplatzer Amulet and continuing single antiplatelet agent up until 6 months

DRUG

long-term treatment with a single antiplatelet agent

continuing long-term treatment with single antiplatelet agent

DRUG

6 months treatment with a single antiplatelet agent

continuing single antiplatelet agent up until 6 months

Trial Locations (1)

04-628

RECRUITING

National Institute of Cardiology, Warsaw